Serveur d'exploration SRAS - Exploration (Accueil)

Index « KwdFr.i » - entrée « Pneumopathie virale (traitement médicamenteux) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Pneumopathie virale (sang) < Pneumopathie virale (traitement médicamenteux) < Pneumopathie virale (transmission)  Facettes :

List of bibliographic references indexed by Pneumopathie virale (traitement médicamenteux)

Number of relevant bibliographic references: 36.
[0-20] [0 - 20][0 - 36][20-35][20-40]
Ident.Authors (with country if any)Title
000029 (2020) Yu-Shi Zhang [République populaire de Chine] ; Wei-Hong Cong [République populaire de Chine] ; Jing-Jing Zhang [République populaire de Chine] ; Fei-Fei Guo [République populaire de Chine] ; Hong-Mei Li [République populaire de Chine][Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].
000032 (2020) Ming Niu [République populaire de Chine] ; Rui-Lin Wang [République populaire de Chine] ; Zhong-Xia Wang [République populaire de Chine] ; Ping Zhang [République populaire de Chine] ; Zhao-Fang Bai [République populaire de Chine] ; Jing Jing [République populaire de Chine] ; Yu-Ming Guo [République populaire de Chine] ; Xu Zhao [République populaire de Chine] ; Xiao-Yan Zhan [République populaire de Chine] ; Zi-Teng Zhang [République populaire de Chine] ; Xue-Ai Song [République populaire de Chine] ; En-Qiang Qin [République populaire de Chine] ; Jia-Bo Wang [République populaire de Chine] ; Xiao-He Xiao [République populaire de Chine][Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].
000035 (2020) H. Li [République populaire de Chine] ; Y M Wang [République populaire de Chine] ; J Y Xu [République populaire de Chine] ; B. Cao [République populaire de Chine][Potential antiviral therapeutics for 2019 Novel Coronavirus].
000050 (2020) Cai-Xia Yan [République populaire de Chine] ; Jia Li [République populaire de Chine] ; Xin Shen [République populaire de Chine] ; Li Luo [République populaire de Chine] ; Yan Li [République populaire de Chine] ; Ming-Yuan Li [République populaire de Chine][Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019].
000062 (2020) Binqing Fu [République populaire de Chine] ; Xiaoling Xu [République populaire de Chine] ; Haiming Wei [République populaire de Chine]Why tocilizumab could be an effective treatment for severe COVID-19?
000101 (2020) Yang Yang ; Md Sahidul Islam ; Jin Wang ; Yuan Li ; Xin ChenTraditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective
000104 (2020) Sean Ekins [États-Unis] ; Thomas R. Lane [États-Unis] ; Peter B. Madrid [États-Unis]Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.
000108 (2020) David CyranoskiThis scientist hopes to test coronavirus drugs on animals in locked-down Wuhan.
000110 (2020) Guangdi Li ; Erik De ClercqTherapeutic options for the 2019 novel coronavirus (2019-nCoV).
000184 (2020) Naidi Yang [République populaire de Chine] ; Han-Ming Shen [République populaire de Chine]Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19
000218 (2020) Daniel Batlle [États-Unis] ; Jan Wysocki [États-Unis] ; Karla Satchell [États-Unis]Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
000258 (2020) Jun Zheng [République populaire de Chine]SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat
000316 (2020) Manli Wang [République populaire de Chine] ; Ruiyuan Cao [République populaire de Chine] ; Leike Zhang [République populaire de Chine] ; Xinglou Yang [République populaire de Chine] ; Jia Liu [République populaire de Chine] ; Mingyue Xu [République populaire de Chine] ; Zhengli Shi [République populaire de Chine] ; Zhihong Hu [République populaire de Chine] ; Wu Zhong [République populaire de Chine] ; Gengfu Xiao [République populaire de Chine]Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
000321 (2020) Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000430 (2020) Juan Simon Rico-Mesa [États-Unis] ; Averi White [États-Unis] ; Allen S. Anderson [États-Unis]Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
000463 (2020) Mirko Baglivo [Italie] ; Manuela Baronio [Italie] ; Giuseppe Natalini [Italie] ; Tommaso Beccari [Italie] ; Pietro Chiurazzi [Italie] ; Ezio Fulcheri [Italie] ; Paolo Pietro Petralia [Italie] ; Sandro Michelini [Italie] ; Giovanni Fiorentini [Italie] ; Giacinto Abele Miggiano [Italie] ; Assunta Morresi [Italie] ; Gerolamo Tonini [Italie] ; Matteo Bertelli [Italie]Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?
000474 (2020) Paolo Calligari [Italie] ; Sara Bobone [Italie] ; Giorgio Ricci [Italie] ; Alessio Bocedi [Italie]Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs.
000511 (2020) Jared S. Morse ; Tyler Lalonde ; Shiqing Xu ; Wenshe Ray LiuLearning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV†
000536 (2020) M. Bizzarri [Italie] ; A S Laganà ; D. Aragona ; V. UnferInositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
000560 (2020) Claudia Cava [Italie] ; Gloria Bertoli [Italie] ; Isabella Castiglioni [Italie]In Silico Discovery of Candidate Drugs against Covid-19.
000580 (2020) Ling Lin [République populaire de Chine] ; Lianfeng Lu [République populaire de Chine] ; Wei Cao [République populaire de Chine] ; Taisheng Li [République populaire de Chine]Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i -k "Pneumopathie virale (traitement médicamenteux)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i  \
                -Sk "Pneumopathie virale (traitement médicamenteux)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdFr.i
   |clé=    Pneumopathie virale (traitement médicamenteux)
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021